New York City, New York, March 17, 2016: Persistence Market Research (PMR) has recently announced the publication of a research report on the global next-generation antibody therapeutics market. According to the report, titled “Global Next-generation Antibody Therapeutics Market Expected to Progress US$ 6,761.1 Million by 2022”, the next-generation antibody therapeutics market is projected to expand at a healthy CAGR of 13% between 2014 and 2022 and reach a market value of US$6,761.1 million by 2022. For 2015, analysts at PMR have projected a market value of US$2,250.0 million. (more…)
Next-generation antibody based therapeutics refers to the use of new and improved therapeutic antibody to create innovative medicines for the treatment of various diseases. Next-generation antibody therapeutics is developed clinically by biotechnology and pharmaceutical companies for various diseases indication. These new therapeutic antibodies are developed with the special features such as increased selectivity and enhance efficacy. Technological advancement such as antibody drug conjugates (ADCs), success of monoclonal antibody (MAb) and antibody-derived therapeutics and increasing demand for biological drugs for the treatment for various chronic diseases are some of the main factors which helps to drive the market. On the basis of technology, next-generation antibody therapeutics market can be segmented into engineered antibodies, bispecific antibodies (bisAbs), antibody-drug conjugates (ADCs), antibody fragments and antibody-like proteins and biosimilar antibody products. ADCs are composed by linking of an antibody with cytotoxic drugs. On the basis of platform, next-generation antibody therapeutics market can be segmented into BioWa. Glycart and xencor. On the basis of therapeutic area, next-generation antibody therapeutics market can be segmented into oncology, autoimmune/inflammatory, haemostasis, ocular disorders, various infectious diseases and others.
Complete report available at Global Next-Generation Antibody Therapeutics Market